ACT Brief: Data Capture vs. Execution, Coordinator Performance Gaps, and COVID Vaccine Composition Vote

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In a new video interview, Abraham Gutman, founder and CEO of AG Mednet, explained why data capture advances have not addressed the underlying execution problem in clinical trials and what a practical operational architecture for AI actually looks like in real-world deployment.
• A new study published by Norman Goldfarb of the Site Council found study coordinators identify only 45% of critical and major problems during document reviews, with substantial variability across experience levels. However, focused training can improve detection rates from 45% to approximately 68%, with performance gaps highest in protocol requirements and lowest in delegation of authority.
• The FDA's vaccine advisory panel is voting on whether COVID-19 vaccines for 2026–2027 should target the XFG variant, based on CDC data more than a month old. The panel faces significant surveillance gaps including declining sequencing volumes and reduced state-local data sharing, leaving real-time variant assessment increasingly difficult.

That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.